Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences

[1]  A. Hochberg,et al.  The oncofetal H19 RNA connection: hypoxia, p53 and cancer. , 2010, Biochimica et biophysica acta.

[2]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[3]  D. Lamm,et al.  Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. , 2008, The Journal of urology.

[4]  R. Goldberg,et al.  First-line therapeutic strategies in metastatic colorectal cancer. , 2008, Oncology.

[5]  A. Hochberg,et al.  The H19 Non-Coding RNA Is Essential for Human Tumor Growth , 2007, PloS one.

[6]  D. Katsaros,et al.  Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[7]  G. Brewer,et al.  The RNA-binding Protein IMP-3 Is a Translational Activator of Insulin-like Growth Factor II Leader-3 mRNA during Proliferation of Human K562 Leukemia Cells* , 2005, Journal of Biological Chemistry.

[8]  M. Hashida,et al.  Disposition and gene expression characteristics in solid tumors and skeletal muscle after direct injection of naked plasmid DNA in mice. , 2003, Journal of pharmaceutical sciences.

[9]  A. Hochberg,et al.  Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  A. Irie.  Advances in gene therapy for bladder cancer. , 2003, Current gene therapy.

[11]  A. Hoffman,et al.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. , 2003, The Journal of clinical investigation.

[12]  Yunbo Shi,et al.  Novel double promoter approach for identification of transgenic animals: A tool for in vivo analysis of gene function and development of gene‐based therapies , 2002, Molecular reproduction and development.

[13]  A. Hochberg,et al.  The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma , 2000, Molecular pathology : MP.

[14]  Y. Fujita-Yamaguchi,et al.  A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[15]  Y. Fujita-Yamaguchi,et al.  Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. , 2000, Biochemical and biophysical research communications.

[16]  Y. M. Lee,et al.  Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. , 1999, Cancer research.

[17]  A. Hochberg,et al.  The expression of the H19 gene and its function in human bladder carcinoma cell lines , 1999, FEBS letters.

[18]  W. Engström,et al.  Transcriptional regulation and biological significance of the insulin like growth factor II gene , 1998, Cell proliferation.

[19]  A. Reeve,et al.  Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. , 1998, Molecular medicine today.

[20]  S. Wilczynski,et al.  Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors , 1998, Cell and Tissue Research.

[21]  A. Hochberg,et al.  Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. , 1998, Molecular pathology : MP.

[22]  R. Weksberg,et al.  Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. , 1997, Biochemical and biophysical research communications.

[23]  V. Erdmann,et al.  The product of the imprinted H19 gene is an oncofetal RNA. , 1997, Molecular pathology : MP.

[24]  K. Mislick,et al.  Evidence for the role of proteoglycans in cation-mediated gene transfer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Sohda,et al.  Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[26]  M. Cooper.  Noninfectious gene transfer and expression systems for cancer gene therapy. , 1996, Seminars in oncology.

[27]  R. Ohlsson,et al.  Normal development and neoplasia: the imprinting connection. , 1995, The International journal of developmental biology.

[28]  M. Pazin,et al.  An enhancer deletion affects both H19 and Igf2 expression. , 1995, Genes & development.

[29]  A. Hochberg,et al.  The imprinted H19 gene as a tumor marker in bladder carcinoma. , 1995, Urology.

[30]  T. Ekström,et al.  Promoter-specific IGF2 imprinting status and its plasticity during human liver development. , 1995, Development.

[31]  G. Veenstra,et al.  Differential expression of the human, mouse and rat IGF-II genes , 1993, Regulatory Peptides.

[32]  C. Polychronakos,et al.  Parental genomic imprinting of the human IGF2 gene , 1993, Nature Genetics.

[33]  I. Maxwell,et al.  Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. , 1992, Leukemia & lymphoma.

[34]  J. Sussenbach,et al.  Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. , 1990, Biochimica et biophysica acta.

[35]  R. A. van der Kammen,et al.  Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. , 1988, Biochimica et biophysica acta.

[36]  W. Catalona,et al.  Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. , 1984, Cancer research.

[37]  L. Tentori,et al.  Recent approaches to improve the antitumor efficacy of temozolomide. , 2009, Current medicinal chemistry.

[38]  A. Hochberg,et al.  The Oncofetal H19 RNA in human cancer, from the bench to the patient , 2005 .

[39]  O. Gofrit,et al.  Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer , 2004 .

[40]  K. Ragnarsson,et al.  Cancer of the Genitourinary System , 2003 .

[41]  K. Pavelić,et al.  The Role of Insulin-Like Growth Factor 2 and Its Receptors in Human Tumors , 2002, Molecular medicine.

[42]  Maciej Szymanski,et al.  The non-coding RNAs as riboregulators , 2001, Nucleic Acids Res..

[43]  G. Kouraklis.  Gene therapy for cancer: from the laboratory to the patient. , 2000, Digestive diseases and sciences.

[44]  M. Imamura,et al.  Possible paracrine mechanism of insulin‐like growth factor‐2 in the development of liver metastases from colorectal carcinoma , 1999, Cancer.

[45]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .